Omnicell

Omnicell sells the automated dispensing cabinets sitting next to roughly 60% of US hospital med-rooms — the XT and XR product families — plus a fast-growing Advanced Services SaaS layer for IV-room workflow, 340B compliance, central pharmacy dispensing, and specialty pharmacy. The stock fell 78% from the September 2021 peak of 184 USD as hospital capex froze post-COVID, EHR vendors tightened middleware fees, and the original XT cabinet refresh cycle paused.

The set-up has changed in three concrete ways through Q1/2026. First, the XTExtend program — a console-only swap on existing XT cabinets that adds Generation-3 software for ~25% the cost of a full replacement — is driving the first sequential US bookings growth in seven quarters (+12% QoQ in Q1/2026). Second, the IVX Workflow product is the Omnicell answer to the FDA-driven 503B compounding crisis: after the 2024-2025 wave of sterile-compounding errors and the November 2025 FDA Guidance for Industry on USP 797/800 enforcement, hospitals are forced to either outsource IV compounding or automate it — and Omnicell is the only US vendor with a one-pass IVX-Compounding-Suite. Third, Advanced Services revenue grew 22% YoY in Q1/2026 to 87M USD and now represents a fully recurring 36% of total revenue.

The thesis pivot is from a one-time capex hardware story to a hardware-pulls-SaaS story where the recurring revenue stream re-rates the multiple over 2026-2028. CEO Nchacha Etta (former Honeywell Connected Industrial COO, joined September 2024) explicitly framed FY 2026 guidance around 20%+ Advanced Services growth and a return to GAAP operating profitability in H2/2026.

Form 4 activity in Q1-Q2/2026 shows a clear long-side conviction setup. CEO Nchacha Etta bought 12,000 shares at 39.20 USD on March 6, 2026 — his first open-market buy since joining. CFO Nchole Brown-Bayer added 8,000 shares at 41.50 USD on March 12. Two independent directors (Bruce Scott, Mark Smith) added a combined 15,000 shares between February and April 2026. Total insider buying since Q4/2025: ~1.6M USD. The last cluster of insider buying of comparable size happened in November 2018 — and Omnicell stock was up 240% in the following 24 months from that level.

13F highlights Q1/2026: Wasatch Advisors remains the largest active long at 8.94% of float (4.1M shares, ~177M USD), unchanged QoQ — they have owned OMCL through the entire 78% drawdown. Brown Capital Management increased by 14% to 2.8M shares (~120M USD). Massachusetts Financial Services (MFS) initiated a 1.6M-share position in Q4/2025 and grew to 2.2M shares in Q1/2026 — fresh new-buyer signal. BlackRock and Vanguard are passive holders only.

Short interest: peaked at 11.4% of float in October 2024 during the worst of the EHR-middleware-fee narrative; now at 5.8% as of April 2026 settlement. Days to cover dropped from 9.2 to 3.1.

OMCL at 43.12 USD trades at 19.6× consensus 2026 EPS of 2.20 USD, 1.6× sales, and 1.58× book. Health-tech automation peers: BD Medical (24× fwd P/E), Stericycle (17×), Henry Schein (16×). The Advanced Services mix-shift to ~45% of revenue by 2027 should support a fair multiple of 22-26× forward EPS — fair value 48-57 USD per share, 11-32% upside on consensus. Bull case with IVX deployments accelerating from 50 to 120 per year and SaaS reaching 45% of revenue: 60-72 USD (39-67% upside). Bear case where hospital capex stays frozen and Epic launches a first-party module: 28-32 USD (26-35% downside). The asymmetry sits in the IVX optionality and the insider-buy cluster, not in the headline multiple.

1. August 4, 2026: Q2/2026 earnings — second consecutive booking growth print would confirm cycle restart, plus first IVX pipeline conversion update
2. September 2026: Omnicell Innovation Forum annual conference — typical venue for new product announcements and customer adoption metrics
3. Q4/2026: FDA final rule on USP 797/800 sterile compounding enforcement — direct lever on IVX demand acceleration

Omnicell is the second-derivative play on the hospital-pharmacy automation cycle. The first derivative — hardware demand returning — is plausibly inflecting per the Q1/2026 booking print. The second derivative — SaaS Advanced Services compounding on top of the hardware base — is what re-rates the multiple. The IVX/503B narrative is the kicker: I do not need it to work to underwrite this stock at 19.6× forward, but if it works the stock probably doubles. Insider buying at 39 USD from a CEO 18 months into the job is meaningful. I am long with a 1.5% portfolio weight, average cost 35 USD. My add trigger is back below 40 USD; my trim trigger is above 60 USD. The catalyst I am watching most closely is the FDA Q4/2026 USP 797/800 final rule — that is when IVX adoption stops being optional for hospitals.